Levipil 250 Tablet contains Levetiracetam 250 mg, an antiepileptic medication primarily indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. It is commonly prescribed as adjunctive therapy in adults and pediatric patients over the age of 4 years. Levipil 250 is well-tolerated, with a favorable pharmacokinetic profile characterized by rapid absorption, minimal protein binding, and predominantly renal excretion. Dosage should be individualized based on clinical response and renal function, with gradual titration to minimize adverse effects. Common side effects include somnolence, dizziness, headache, and fatigue, while serious adverse reactions such as behavioral changes, mood disturbances, or hypersensitivity are less frequent but warrant close monitoring. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Levipil 250 Tablet should be used under strict medical supervision, with regular follow-up to assess efficacy and tolerability. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any excipients.